COMMUNIQUÉS West-GlobeNewswire

-
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
04/12/2018 -
TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
04/12/2018 -
Dermira Enters into Credit Facility with Athyrium Capital Management
04/12/2018 -
Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
04/12/2018 -
ExCellThera announces results of clinical trial using ECT-001 for blood cancers
04/12/2018 -
Tetra Bio-Pharma Convenes First National Medical Advisory Board
04/12/2018 -
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04/12/2018 -
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
04/12/2018 -
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
04/12/2018 -
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
04/12/2018 -
RavenQuest Begins Cannabis Sales
04/12/2018 -
INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
04/12/2018 -
Transactions in relation to share buyback program
04/12/2018 -
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
04/12/2018 -
Rule 2.9 Announcement
04/12/2018 -
Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China
04/12/2018 -
Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies
04/12/2018 -
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
04/12/2018 -
Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
04/12/2018
Pages